According to the University of Macau (UM) on the 4th, in order to cooperate with the Macao Special Administrative Region Government’s “1+4” moderate economic diversification development strategy and promote the development of Macao’s big health industry, UM and China National Pharmaceutical Group Co., Ltd. (Sinopharm Group) recently signed a strategic cooperation agreement in the field of big health.

Both parties hope to promote the transformation of Australia's scientific research results through closer industry-university-research cooperation, and help enhance the scientific and technological strength of the biomedicine and health strategy.

Liu Jingzhen, Chairman of China National Pharmaceutical Group Co., Ltd., led a delegation to visit the University of Adelaide on February 26. The delegation members included leaders of Sinopharm Group and representatives of subsidiaries in different fields such as traditional Chinese medicine , biopharmaceuticals, chemical pharmaceuticals, and medical aesthetics.

UM Rector Yonghua Song briefed the delegation on UM’s recent development, strengths and future development plans, as well as UM’s development priorities and achievements in health sciences and traditional Chinese medicine. He said UM highly values cooperation with Sinopharm and will do its utmost to advance the cooperation.

Subsequently, UM and Sinopharm Group jointly signed a strategic cooperation agreement in the field of big health. UM said that the signing of the agreement marks that the two sides will carry out in-depth cooperation in the construction of joint laboratories, cooperation in translational research and commercialization of scientific research results, and strengthening talent training in the field of big health based on the principle of complementary advantages and common development.

The delegation then visited the State Key Laboratory of Quality Research in Chinese Medicines and the Faculty of Health Sciences of UM, and held an exchange seminar. At the meeting, UM professors further introduced seven research results, including health care, anti-cancer, medical beauty, and reagents, based on the previous docking and discussions between the two sides. Representatives of Sinopharm, Sinopharm Holding, and Modern Pharmaceutical, subsidiaries of Sinopharm Group, introduced their respective company profiles, cooperation intentions and cooperation models with UM.

The enterprise is directly managed by the State-owned Assets Supervision and Administration Commission of the State Council, with life sciences and health as its main business . It comprehensively serves the "Healthy China" strategy. The group's scale, efficiency and comprehensive strength are in a leading position in the global industry.

http://www.zlb.gov.cn/2024-03/05/c_1212338812.htm